Skip to main content
Premium Trial:

Request an Annual Quote

MWG Biotech to Exit Microarray and Lab Automation Businesses

This article has been updated from an earlier version.

NEW YORK, Oct. 8 (GenomeWeb News) - Ebersberg, Germany-based MWG Biotech today said that it plans to divest its microarray and lab automation businesses.

In a statement, the company said that managment will consider "various separation" options for the divestiture of the product lines to focus on its genomic synthesis business, the production of synthetic nucleic acids and oligonucleotides, and genomic information (DNA sequencing).

The company said it expects a negative impact on its financials, but was not able to provide any specific guidance, but said it will seek new capital.

MWG was founded in 1990 and added its genomic diagnostics (microarrays) division in 2000.



The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.